A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses via Oral Administration to Healthy Participants

Study identifier:D9440C00001

ClinicalTrials.gov identifier:NCT06122714

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I Randomised, Single-blind, Placebo-controlled, and Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses via Oral Administration to Healthy Participants

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD4144 Part A, AZD4144 Part B, Placebo Part A, Placebo Part B

Sex

All

Estimated Enrollment

104

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 07 Nov 2023
Estimated Primary Completion Date: 09 Aug 2024
Estimated Study Completion Date: 09 Aug 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria